Skip to main content
main-content

Type 2 diabetes


Browse the latest news, expert commentary, and educational content on type 2 diabetes.


Highlights

Piggy bank balancing on seesaw over a bottle of pills

10-04-2022 | Healthcare costs | News

First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

Overweight women have examination at dietitian-nutritionist's office (symbolic image with model)

09-23-2022 | EASD 2022 | Conference coverage | News

ADA/EASD hyperglycemia management consensus update strengthens holistic care

The latest update to the ADA and EASD hyperglycemia management consensus report places a strong emphasis on holistic, person-centered care for type 2 diabetes.

Girl with CGM

09-21-2022 | EASD 2022 | Conference coverage | News

Skin reactions rarely lead to diabetes device discontinuation

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

More on type 2 diabetes

The SURPASS trials

Get the latest reporting, researcher interviews, and independent commentary on tirzepatide for type 2 diabetes.

Semaglutide for weight loss: The STEP and SELECT trials

Get the latest results and insights from the researchers.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox